HUE048111T2 - Anti-CEACAM6 ellenanyagok és alkalmazásuk - Google Patents

Anti-CEACAM6 ellenanyagok és alkalmazásuk

Info

Publication number: HUE048111T2
Authority: HU; Hungary
Prior art keywords: application; ceacam6 antibodies; ceacam6; antibodies
Prior art date: 2015-03-23

Application number

HUE16713784A

Other languages

English (en)

Inventor

Joerg Willuda

Mark Trautwein

Uwe Gritzan

Christoph Freiberg

Frank Dittmer

Dorian Schoenfeld

Julian Glueck

Jessica Pinkert

Eva-Maria Gutierrez

Sven Golfier

Simon Holton

Philip Beckhove

Yingzi Ge

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-23

Filing date

2016-03-21

Publication date

2020-05-28

2016-03-21 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2020-05-28 Publication of HUE048111T2 publication Critical patent/HUE048111T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4238—Regulators of development
- A61K40/424—Apoptosis related proteins, e.g. survivin or livin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4264—Cancer antigens from embryonic or fetal origin
- A61K40/4266—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Endocrinology (AREA)
Analytical Chemistry (AREA)
Mycology (AREA)
Plant Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Peptides Or Proteins (AREA)

HUE16713784A 2015-03-23 2016-03-21 Anti-CEACAM6 ellenanyagok és alkalmazásuk HUE048111T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15160292		2015-03-23

Publications (1)

Publication Number	Publication Date
HUE048111T2 true HUE048111T2 (hu)	2020-05-28

Family

ID=52692556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE16713784A HUE048111T2 (hu)	2015-03-23	2016-03-21	Anti-CEACAM6 ellenanyagok és alkalmazásuk

Country Status (28)

Country	Link
US (3)	US10584167B2 (hu)
EP (2)	EP3628688A1 (hu)
JP (2)	JP6815329B2 (hu)
KR (1)	KR102749339B1 (hu)
CN (1)	CN107743495B (hu)
AR (1)	AR104047A1 (hu)
AU (1)	AU2016236270B2 (hu)
BR (1)	BR112017020373A2 (hu)
CA (1)	CA2980390A1 (hu)
CY (1)	CY1122627T1 (hu)
DK (1)	DK3274370T3 (hu)
ES (1)	ES2768784T3 (hu)
HK (1)	HK1246312A1 (hu)
HR (1)	HRP20192280T1 (hu)
HU (1)	HUE048111T2 (hu)
IL (1)	IL254534B (hu)
LT (1)	LT3274370T (hu)
MX (1)	MX376973B (hu)
PE (1)	PE20171790A1 (hu)
PL (1)	PL3274370T3 (hu)
PT (1)	PT3274370T (hu)
RS (1)	RS59878B1 (hu)
RU (1)	RU2739163C2 (hu)
SG (1)	SG11201707800QA (hu)
SI (1)	SI3274370T1 (hu)
TW (1)	TWI719969B (hu)
WO (1)	WO2016150899A2 (hu)
ZA (1)	ZA201707138B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2768784T3 (es)	2015-03-23	2020-06-23	Bayer Pharma AG	Anticuerpos anti-CEACAM6 y usos de los mismos
KR102726248B1 (ko)	2016-07-07	2024-11-05	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	항체-애쥬번트 접합체
JP7032412B2 (ja)	2016-10-10	2022-03-08	シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド	抗ｃｅａｃａｍ６抗体及び使用方法
MX2019005491A (es) *	2016-11-14	2019-08-12	Dinona	Anticuerpo que enlaza especificamente a cd66c y uso del mismo.
KR102014400B1 (ko) *	2017-01-05	2019-08-28	한국생명공학연구원	Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체
US11623953B2 (en)	2017-02-27	2023-04-11	Caerus Therapeutics, Inc.	Antibody constructs and methods of treating cancer
AU2018258027A1 (en) *	2017-04-24	2019-10-24	Memorial Sloan Kettering Cancer Center	Anti-CD33 antibody agents
CN111065653A (zh) *	2017-05-23	2020-04-24	中央研究院	藉由预靶向的双特异性聚乙二醇结合抗体将聚乙二醇化试剂条件性内吞用于诊断和治疗
CA3070789A1 (en) *	2017-08-10	2019-02-14	Grifols Diagnostic Solutions Inc.	Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
KR102134954B1 (ko)	2018-01-08	2020-07-16	충북대학교 산학협력단	CEACAM6 발현 억제를 위한 siRNA 및 이를 포함하는 선암 치료제
EP3752533A4 (en) *	2018-02-13	2021-05-05	Precision Biologics, Inc.	Methods and compositions for targeting treg cells
JP7451415B2 (ja) *	2018-03-13	2024-03-18	タスクセラピューティクスリミテッド	腫瘍特異的細胞枯渇のための抗ｃｄ２５
KR102373502B1 (ko)	2018-05-14	2022-03-11	주식회사 금호에이치티	골수유래억제세포 관련 질환의 예방 및 치료 용도
SG11202011024WA (en) *	2018-05-23	2020-12-30	Beigene Ltd	Anti-ox40 antibodies and methods of use
CA3119563A1 (en)	2018-11-14	2020-05-22	Bayer Aktiengesellschaft	Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
MX2021007369A (es)	2018-12-19	2021-07-15	Bayer Ag	Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3.
AU2020241686A1 (en)	2019-03-15	2021-11-04	Bolt Biotherapeutics, Inc.	Immunoconjugates targeting HER2
JP7554781B2 (ja) *	2019-06-04	2024-09-20	普米斯生物技術（珠海）有限公司	抗ｃｅａｃａｍ５モノクローナル抗体およびその調製方法およびその使用
US20220401374A1 (en) *	2019-09-13	2022-12-22	Purdue Research Foundation	Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
US20230115540A1 (en) *	2020-03-06	2023-04-13	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Tumor targeted fluorescence guidance for intraoperative margin assessment
CN111533808B (zh) *	2020-03-10	2021-02-09	南京医科大学	一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
CN113637073B (zh) *	2020-05-11	2024-04-12	上海赛比曼生物科技有限公司	Bcma抗体及其制备和应用
CN112457402B (zh) *	2020-10-21	2022-08-30	北京纽安博生物技术有限公司	抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用
WO2022116079A1 (zh) *	2020-12-03	2022-06-09	上海吉倍生物技术有限公司	一种抗ceacam5的人源化抗体及其制备方法和用途
MX2023006882A (es) *	2020-12-11	2024-02-15	Materia Therapeutics Inc	Tratamiento contra el cancer usando bosentan en combinacion con un inhibidor de puntos de control.
CA3205463A1 (en) *	2020-12-18	2022-06-23	Bioardis, Llc	Cea6 binding molecules and uses thereof
CN112521509B (zh) *	2020-12-23	2022-07-08	姚雪英	一种抗ceacam5人源化抗体、其缀合物及其用途
WO2023031366A1 (en)	2021-09-02	2023-03-09	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Anti-cecam6 antibodies with reduced side-effects
IL315205A (en)	2022-03-23	2024-10-01	Synaffix Bv	Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
CN116196415B (zh) *	2022-12-07	2023-08-01	浙江省肿瘤医院	用于增敏pd-1抗体的混合制剂及其使用方法
WO2024243217A1 (en) *	2023-05-25	2024-11-28	BioLegend, Inc.	Ceacam6 binding antibodies and antigen-binding fragments thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
PT859841E (pt)	1995-08-18	2002-11-29	Morphosys Ag	Bibliotecas de proteinas/ (poli) peptidos
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
JP2002506353A (ja)	1997-06-24	2002-02-26	ジェネンテック・インコーポレーテッド	ガラクトシル化糖タンパク質の方法及び組成物
AU759779B2 (en)	1997-10-31	2003-05-01	Genentech Inc.	Methods and compositions comprising glycoprotein glycoforms
ATE531812T1 (de)	1997-12-05	2011-11-15	Scripps Research Inst	Humanisierung von nager-antikörpern
PT1068241E (pt)	1998-04-02	2007-11-19	Genentech Inc	Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en)	2002-12-16	2008-07-16	Genentech, Inc.	Immunoglobulin variants and uses thereof
RS55723B1 (sr)	2003-11-05	2017-07-31	Roche Glycart Ag	Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
PT2489364E (pt)	2003-11-06	2015-04-16	Seattle Genetics Inc	Compostos de monometilvalina conjugados com anticorpos
JP5128935B2 (ja)	2004-03-31	2013-01-23	ジェネンテック，インコーポレイテッド	ヒト化抗ＴＧＦ−β抗体
AU2006244885B2 (en)	2005-05-09	2011-03-31	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko)	2005-07-01	2018-08-13	이. 알. 스퀴부 앤드 선즈, 엘.엘.씨.	예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008156712A1 (en)	2007-06-18	2008-12-24	N. V. Organon	Antibodies to human programmed death receptor pd-1
EA023148B1 (ru)	2008-08-25	2016-04-29	Эмплиммьюн, Инк.	Композиции на основе антагонистов pd-1 и их применение
EP4331604B1 (en)	2008-12-09	2025-03-05	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3009455A1 (en)	2009-09-16	2016-04-20	Immunomedics Inc.	Class i anti-cea antibodies and uses thereof
SI3279215T1 (sl)	2009-11-24	2020-07-31	Medimmune Limited	Usmerjena vezavna sredstva proti B7-H1
US8404812B2 (en) *	2010-02-26	2013-03-26	Dinona Inc.	Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
US20130189268A1 (en)	2010-06-22	2013-07-25	Precision Biologics, Inc.	Colon and pancreas cancer specific antigens and antibodies
US9066986B2 (en)	2010-10-01	2015-06-30	National Research Council Of Canada	Anti-CEACAM6 antibodies and uses thereof
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
ES2808152T3 (es)	2011-11-28	2021-02-25	Merck Patent Gmbh	Anticuerpos anti-PD-L1 y usos de los mismos
RU2493166C1 (ru) *	2012-04-09	2013-09-20	Общество с ограниченной ответственностью "Технофарма"	Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
EP2850102A1 (en)	2012-05-15	2015-03-25	Bristol-Myers Squibb Company	Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10131712B2 (en)	2012-08-14	2018-11-20	Ibc Pharmaceuticals, Inc.	Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
AU2013400609B9 (en)	2013-09-13	2020-03-05	Beigene Switzerland Gmbh	Anti-PD1 antibodies and their use as therapeutics and diagnostics
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2768784T3 (es) *	2015-03-23	2020-06-23	Bayer Pharma AG	Anticuerpos anti-CEACAM6 y usos de los mismos
CN107847589B (zh)	2015-04-01	2022-03-29	安奈普泰斯生物有限公司	针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
EP3443009B1 (en)	2016-04-12	2021-09-08	Symphogen A/S	Anti-tim-3 antibodies and compositions
SG11201810023QA (en)	2016-05-27	2018-12-28	Agenus Inc	Anti-tim-3 antibodies and methods of use thereof
KR102493282B1 (ko)	2016-07-14	2023-02-01	브리스톨-마이어스 스큅 컴퍼니	Tim3에 대한 항체 및 그의 용도
JOP20190013A1 (ar)	2016-08-25	2019-01-31	Lilly Co Eli	أجسام مضادة لـ (تي آي ام -3)
MX2019005491A (es)	2016-11-14	2019-08-12	Dinona	Anticuerpo que enlaza especificamente a cd66c y uso del mismo.
TWI841209B (zh)	2017-01-09	2024-05-01	美商提薩羅有限公司	用抗tim-3抗體治療癌症之方法

2016
- 2016-03-21 ES ES16713784T patent/ES2768784T3/es active Active
- 2016-03-21 US US15/561,013 patent/US10584167B2/en active Active
- 2016-03-21 CN CN201680024895.XA patent/CN107743495B/zh active Active
- 2016-03-21 RU RU2017137010A patent/RU2739163C2/ru active
- 2016-03-21 KR KR1020177029946A patent/KR102749339B1/ko active Active
- 2016-03-21 EP EP19202632.6A patent/EP3628688A1/en active Pending
- 2016-03-21 LT LTEP16713784.3T patent/LT3274370T/lt unknown
- 2016-03-21 WO PCT/EP2016/056104 patent/WO2016150899A2/en active Application Filing
- 2016-03-21 EP EP16713784.3A patent/EP3274370B1/en active Active
- 2016-03-21 PE PE2017001579A patent/PE20171790A1/es unknown
- 2016-03-21 JP JP2017549507A patent/JP6815329B2/ja active Active
- 2016-03-21 HU HUE16713784A patent/HUE048111T2/hu unknown
- 2016-03-21 TW TW105108621A patent/TWI719969B/zh active
- 2016-03-21 BR BR112017020373-1A patent/BR112017020373A2/pt not_active IP Right Cessation
- 2016-03-21 PL PL16713784T patent/PL3274370T3/pl unknown
- 2016-03-21 PT PT167137843T patent/PT3274370T/pt unknown
- 2016-03-21 CA CA2980390A patent/CA2980390A1/en active Pending
- 2016-03-21 DK DK16713784.3T patent/DK3274370T3/da active
- 2016-03-21 RS RS20200132A patent/RS59878B1/sr unknown
- 2016-03-21 MX MX2017012278A patent/MX376973B/es active IP Right Grant
- 2016-03-21 AU AU2016236270A patent/AU2016236270B2/en active Active
- 2016-03-21 SI SI201630585T patent/SI3274370T1/sl unknown
- 2016-03-21 SG SG11201707800QA patent/SG11201707800QA/en unknown
- 2016-03-22 AR ARP160100772A patent/AR104047A1/es not_active Application Discontinuation
2017
- 2017-09-17 IL IL254534A patent/IL254534B/en unknown
- 2017-10-20 ZA ZA2017/07138A patent/ZA201707138B/en unknown
2018
- 2018-05-02 HK HK18105631.4A patent/HK1246312A1/zh unknown
2019
- 2019-12-18 HR HRP20192280TT patent/HRP20192280T1/hr unknown
2020
- 2020-01-29 US US16/776,329 patent/US11866495B2/en active Active
- 2020-01-29 US US16/776,326 patent/US11773164B2/en active Active
- 2020-02-13 CY CY20201100133T patent/CY1122627T1/el unknown
- 2020-12-22 JP JP2020212437A patent/JP7185379B2/ja active Active

Also Published As

Publication number	Publication date
AU2016236270A1 (en)	2017-10-12
BR112017020373A2 (pt)	2018-06-05
HK1246312A1 (zh)	2018-09-07
PL3274370T3 (pl)	2020-05-18
PT3274370T (pt)	2020-01-30
ZA201707138B (en)	2022-11-30
CN107743495A (zh)	2018-02-27
CN107743495B (zh)	2021-05-14
US20200181261A1 (en)	2020-06-11
MX376973B (es)	2025-03-07
SI3274370T1 (sl)	2020-02-28
JP6815329B2 (ja)	2021-01-20
WO2016150899A2 (en)	2016-09-29
TW201713693A (zh)	2017-04-16
TWI719969B (zh)	2021-03-01
US11773164B2 (en)	2023-10-03
DK3274370T3 (da)	2020-02-17
ES2768784T3 (es)	2020-06-23
HRP20192280T1 (hr)	2020-03-06
WO2016150899A3 (en)	2016-11-17
PE20171790A1 (es)	2017-12-28
US20200157214A1 (en)	2020-05-21
US10584167B2 (en)	2020-03-10
RS59878B1 (sr)	2020-03-31
AR104047A1 (es)	2017-06-21
JP2018510636A (ja)	2018-04-19
LT3274370T (lt)	2020-02-10
JP2021058199A (ja)	2021-04-15
KR102749339B1 (ko)	2025-01-03
CA2980390A1 (en)	2016-09-29
EP3274370A2 (en)	2018-01-31
US11866495B2 (en)	2024-01-09
CY1122627T1 (el)	2021-03-12
MX2017012278A (es)	2018-05-23
RU2017137010A (ru)	2019-04-23
US20180162940A1 (en)	2018-06-14
IL254534A0 (en)	2017-11-30
RU2017137010A3 (hu)	2019-12-12
JP7185379B2 (ja)	2022-12-07
RU2739163C2 (ru)	2020-12-21
IL254534B (en)	2021-12-01
EP3274370B1 (en)	2019-11-20
SG11201707800QA (en)	2017-10-30
AU2016236270B2 (en)	2022-01-27
KR20170128567A (ko)	2017-11-22
EP3628688A1 (en)	2020-04-01

Publication	Publication Date	Title
HUE048111T2 (hu)	2020-05-28	Anti-CEACAM6 ellenanyagok és alkalmazásuk
HK1258058A1 (zh)	2019-11-01	抗tigit抗體和使用方法
HK1251587A1 (zh)	2019-02-01	抗磷脂酰肌醇蛋白多糖-3的抗體及其應用
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
HK1252615A1 (zh)	2019-05-31	Il-8-結合抗體及其應用
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1254953A1 (zh)	2019-08-02	抗vista抗體和片段
HUE062927T2 (hu)	2023-12-28	Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
KR102162129B9 (ko)	2023-02-08	항-갈렉틴-9 항체 및 이의 용도
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
KR20180084817A (ko)	2018-07-25	항-siglec-9 항체 및 이의 이용 방법
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
IL254517B (en)	2021-05-31	Antibodies against muc16 and their uses
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
HUE045307T2 (hu)	2019-12-30	EGFRVIII-ellenes antitestek és alkalmazásaik
HUE052771T2 (hu)	2021-05-28	C10orf54 elleni antitestek és alkalmazásuk
DK3368572T3 (da)	2022-08-08	Anti-pd-1-antistoffer og -sammensætninger
PL3148579T3 (pl)	2021-07-19	Przeciwciała anty-gitr i sposoby ich zastosowania
LT3258951T (lt)	2020-05-11	Anti-pvrig antikūnai ir jų panaudojimo būdai
HUE053641T2 (hu)	2021-07-28	Anti-LAG3 antitestek és antigénkötõ fragmentumok
HUE061253T2 (hu)	2023-06-28	Antitestek OX40 ellen és azok felhasználásai
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
HUE047784T2 (hu)	2020-05-28	Anti-TIM3 antitestek és alkalmazási eljárások
HUE060878T2 (hu)	2023-04-28	Anti-transztiretin antitestek
IL258079B (en)	2021-07-29	Antigen receptors and uses thereof